Attorney Docket No .RPP174AUS U.S. Patent Application No. 10/607,922

Date: 08/04/2005

In The Claims

Please amend the claims as follows:

Claims 1-4 (cancelled)

Claim 5 (currently amended) A compound of the formula:

or a phamaceutically acceptable derivative thereof, wherein:

R₁ and R₂ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, $-C(O)R_a$ or $-COOR_a$ or $[[-CH(CH_3)(OR) \text{ or } -CH(CH_3)(O(CH_2)_nXR)]]$ $-CH(CH_3)(OR_a)$ or $-CH(CH_3)(O(CH_2)_nXR_a)$ where R_a is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted cycloalkyl where R2 may be CH-CH2, CH(OR20)CH3, C(O)Me, C(-NR21)CH3 or $CH(NHR_{24})CH_3$; where R_2 may be $-CH=CH_2$, $-CH(OR_{20})CH_3$, -C(O)Me, $-C(=NR_{21})CH_3$ or $-CH(NHR_{24})CH_3$; CH(NHR₂₁)CH₃

where X is an aryl or heteroaryl group;

n is an integer of 0 to 6;

R and R

where R₂₀ is methyl, butyl, heptyl, docecyl or 3,5-bis(trifluoromethyl)-benzyl; and R₂₁ is 3,5,-bis(trifluoromethyl)benzyl;

 R_{1a} and R_{2a} are each independently hydrogen or substituted or unsubstituted alkyl, or together form a covalent bond;

R₃ and R₄ are each independently hydrogen or substituted or unsubstituted alkyl;

 R_{3a} and R_{4a} are each independently hydrogen or substituted or unsubstituted alkyl, or together form a covalent bond;

R₅ is hydrogen or substituted or unsubstituted alkyl;

R₆ and R_{6a} are each independently hydrogen or substituted or unsubstituted alkyl, or together form =0;

 R_7 is a covalent bond, alkylene, azaalkyl, or azaaraalkyl or =NR₂₀ where R₂₀ is 3,5-bis(tri-fluoromethyl)benzyl or -CH₂X-R¹ or -YR¹ where Y is an aryl or heteroaryl group;

 R_8 and R_{8a} are each independently hydrogen or substituted or unsubstituted alkyl or together form =0;

 R_9 and R_{10} are each independently hydrogen, or substituted or unsubstituted alkyl and R_9 may be $-CH_2CH_2COOR^2$ where R^2 is an alkyl group that may optionally substituted with one or more fluorine atoms;

each of R_1 - R_{10} , when substituted, is substituted with one or more substituents each independently selected from Q, where Q is alkyl, haloalkyl, halo, pseudohalo, or -COOR_b where R_b is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, Θ aryl, heteroaryl, araalkyl, or OR_c where R_c is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl or $CONR_dR_e$ where R_d and R_e are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl, or NR_fR_g where R_f and R_g are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl, or aryl, or P0 are P1, where P2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl, or is an amino acid residue;

each Q is independently unsubstituted or is substituted with one or more substituents each independently selected from Q_1 , where Q_1 is alkyl, haloalkyl, halo, pseudohalo, or -COOR_b where R_b is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, Θ aryl, heteroaryl, araalkyl, or OR_c where R_c is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl or $CONR_dR_e$ where R_d and R_e are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl, or NR_fR_g where R_f and R_g are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl, or PR_h where PR_h is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, or aryl, or is an amino acid residue. PR_h

with the proviso that the compound contains at least one fluorine atom in at least one

3,5,-bis(trifluoromethyl)benzyl group or in at least one R, R^1 , or R^2 group.

Claims 6-7 (cancelled)

Claim 8 (previously presented). The compound of claim 5 wherein:

R₁ is methyl;

R_{1a} and R_{2a} together form a covalent bond;

R₃ is methyl;

R₄ is ethyl;

 R_{3a} and R_{4a} are each independently hydrogen, or together form a covalent bond;

R₅ is methyl;

R₉ is CH₂CH₂COOH or CH₂CH₂COOMe;

R₁₀ is methyl.

Claim 9 (previously presented) The compound of claim 5, wherein:

 \mbox{R}_2 is CH=CH2, CH(OR20)CH3, C(O)Me, C(=NR21)CH3 or CH(NHR21)CH3;

where R_{20} is methyl, butyl, heptyl, dodecyl or 3,5-bis(trifluoromethyl)-benzyl; and

R₂₁ is 3,5-bis(trifluoromethyl)benzyl.

Attorney Docket No .RPP174AUS U.S. Patent Application No. 10/607,922

Date: 08/04/2005

Claim 10 (cancelled)

Claim 11 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof.

Claim 12 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof, wherein:

R is methyl, butyl, heptyl or dodecyl.

Claim 13 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof, wherein:

R is methyl, butyl, heptyl or dodecyl.

Claim 14 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof.

Claim 15 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof, wherein:

R is methyl, butyl, heptyl or dodecyl.

Claim 16 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof.

Claim 17 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof.

Claim 18 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof, wherein:

X is an aryl or heteroaryl group;

R and R^1 are each independently alkyl, aryl, or heteroaryl groups having 1 – 20 carbon atoms, wherein at least one of R and R^1 is substituted with at least one fluorine atom; and

R² is an alkyl group, optionally substituted with one or more fluorine atoms.

Claim 19 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof, wherein:

· X is an aryl or heteroaryl group;

n is an integer from 0 to 6;

R and R^1 are each independently alkyl, aryl, or heteroaryl groups having 1 – 20 carbon atoms, wherein at least one of R and R^1 is substituted with at least one fluorine atom; and

 $\ensuremath{\mathsf{R}}^2$ is an alkyl group, optionally substituted with one or more fluorine atoms.

Claim 20 (previously presented) The compound of claim 5 having the formula

or a pharmaceutically acceptable derivative thereof, wherein:

X is an aryl or heteroaryl group;

R and R^1 are each independently alkyl, aryl, or heteroaryl groups having 1-20 carbon atoms, wherein at least one of R and R^1 is substituted with at least one fluorine atom; and

 $\ensuremath{\mathsf{R}}^2$ is an alkyl group, optionally substituted with one or more fluorine atoms.

Claim 21 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof, wherein:

X is an aryl or heteroaryl group;

n is an integer from 0 to 6;

R and R^1 are each independently alkyl, aryl, or heteroaryl groups having 1-20 carbon atoms, wherein at least one of R and R^1 is substituted with at least one fluorine atom; and

R² is an alkyl group, optionally substituted with one or more fluorine atoms.

Claim 22 (previously presented) The compound of claim 5 having the formula:

or a pharmaceutically acceptable derivative thereof, wherein:

X and Y are each independently an aryl or heteroaryl group; n is an integer from 0 to 6;

R and R^1 are each independently alkyl, aryl, or heteroaryl groups having 1 – 20 carbon atoms, wherein at least one of R and R^1 is substituted with at least one fluorine atom; and

R² is an alkyl group, optionally substituted with one or more fluorine atoms.

Claim 23 (previously presented)

A pharmaceutical composition, comprising a compound of claim 1 or a pharmaceutically acceptable derivative thereof in a pharmaceutically acceptable carrier.

Claims 24-121 (cancelled)

Attorney Docket No .RPP174AUS U.S. Patent Application No. 10/607,922

Date: 08/04/2005

Claim 122 (previously presented) The compound of claim 17 or a pharmaceutically acceptable

derivative thereof when used for the detection or treatment or both of hyperproliferative tissue.

Claim 123 (previously presented) The compound of claim 18 or a pharmaceutically acceptable

derivative thereof when used for the detection or treatment or both of hyperproliferative tissue.

Claim 124 (previously presented) The compound of claim 19 or a pharmaceutically acceptable

derivative thereof when used for the detection or treatment or both of hyperproliferative tissue.